|
|
|
|
Direct Cost |
Indirect Cost |
|
1DP1AI169444-01 |
Defining the viral PTMome: Towards the development of novel antiviral approaches |
CLEVELAND CLINIC LERNER COM-CWRU |
NIAID |
$700,000 |
$427,000 |
$1,127,000 |
1F30CA250254-01A1 |
Role of SerpinB3 in glioblastoma cancer stem cells |
CLEVELAND CLINIC LERNER COM-CWRU |
NCI |
$51,036 |
|
$51,036 |
1F31CA257276-01A1 |
Dissecting the roles of a novel immune-checkpoint receptor complex in driving T cell dysfunction in cancers |
CLEVELAND CLINIC LERNER COM-CWRU |
NCI |
$40,090 |
|
$40,090 |
1F31CA264849-01 |
Polyamines drive glioblastoma progression |
CLEVELAND CLINIC LERNER COM-CWRU |
NCI |
$37,225 |
|
$37,225 |
1F31EY033223-01 |
Altered RPE matrix in Sorsby Fundus Dystrophy leads to metabolic dysfunction |
CLEVELAND CLINIC LERNER COM-CWRU |
NEI |
$38,663 |
|
$38,663 |
1F32AA029290-01A1 |
IRF3 activation promotes fibrotic liver injury in alcohol-associated-liver disease |
CLEVELAND CLINIC LERNER COM-CWRU |
NIAAA |
$66,390 |
|
$66,390 |
1F32CA260774-01 |
Bacterial Rogue Methyltransferases Inducing Human Epimutations |
CLEVELAND CLINIC LERNER COM-CWRU |
NCI |
$70,458 |
|
$70,458 |
1F32NS120902-01 |
Optical monitoring of the role of neurogenesis in epileptogenesis |
CLEVELAND CLINIC LERNER COM-CWRU |
NINDS |
$66,390 |
|
$66,390 |
1K01AA029474-01 |
The role of PDK4 in alcohol-associated liver disease |
CLEVELAND CLINIC LERNER COM-CWRU |
NIAAA |
$168,482 |
$13,399 |
$181,881 |
1K08AA028794-01 |
Mechanisms of HIF1 alpha mediated dysregulated skeletal muscle proteostasis in alcoholic liver disease |
CLEVELAND CLINIC LERNER COM-CWRU |
NIAAA |
$165,860 |
$13,269 |
$179,129 |
1K99AA029146-01A1 |
Role of MLKL in Alcohol-associated Liver Disease |
CLEVELAND CLINIC LERNER COM-CWRU |
NIAAA |
$157,711 |
$12,617 |
$170,328 |
1K99CA248611-01A1 |
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma |
CLEVELAND CLINIC LERNER COM-CWRU |
NCI |
$111,528 |
$8,922 |
$120,450 |
1K99GM143552-01 |
Unraveling the PTEN Interactome: Modeling Structural and Functional Dynamic Network Architecture for Therapeutic Modulation in Cancer and Autism |
CLEVELAND CLINIC LERNER COM-CWRU |
NIGMS |
$92,778 |
$7,222 |
$100,000 |
1K99HL153688-01A1 |
MCEMP1 is an adaptor for KIT receptor for mast cell proliferation |
CLEVELAND CLINIC LERNER COM-CWRU |
NHLBI |
$94,222 |
$7,538 |
$101,760 |
1P01HL154811-01A1 |
Cell Adhesion and Signaling in Blood and Vascular Cells |
CLEVELAND CLINIC LERNER COM-CWRU |
NHLBI |
$1,510,000 |
$890,600 |
$2,400,600 |
1P30AG072959-01 |
Cleveland Alzheimers Disease Research Center |
CLEVELAND CLINIC LERNER COM-CWRU |
NIA |
$2,001,627 |
$1,088,616 |
$3,090,243 |
1R01AA028763-01A1 |
Immuno-metabolic dysfunction in alcohol with sepsis |
CLEVELAND CLINIC LERNER COM-CWRU |
NIAAA |
$243,665 |
$148,636 |
$392,301 |
1R01AG070736-01 |
CYCLE-AD: Randomized Controlled Trial to Assess the Efficacy of Indoor Cycling in Slowing Disease Progression in Healthy Older Persons at Genetic Risk for Alzheimers Disease |
CLEVELAND CLINIC LERNER COM-CWRU |
NIA |
$828,947 |
$474,392 |
$1,303,339 |
1R01AG073212-01 |
Repurposing Siponimod for Alzheimers Disease |
CLEVELAND CLINIC LERNER COM-CWRU |
NIA |
$523,088 |
$208,768 |
$731,856 |
1R01AG074392-01 |
Interactions of Sex and Gender Factors in Risk for Alzheimers Disease: Links Between Stress, Neural Activity, Inflammation, and Memory |
CLEVELAND CLINIC LERNER COM-CWRU |
NIA |
$346,466 |
$137,324 |
$483,790 |